These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19416252)

  • 1. Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab.
    Jensen AØ; Møller BK; Vangkilde A; Mark B; Obitz ER; Kragballe K; Iversen L
    Br J Dermatol; 2009 Jun; 160(6):1359-61. PubMed ID: 19416252
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab and its use in autoimmune bullous disorders.
    Daniel BS; Murrell DF; Joly P
    Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Blistering autoimmune dermatoses (II): therapy].
    Goebeler M; Sitaru C; Zillikens D
    J Dtsch Dermatol Ges; 2004 Sep; 2(9):774-91; quiz 792-3. PubMed ID: 16279223
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmune blistering diseases: incidence and treatment in Croatia.
    Marinovic B; Lipozencic J; Jukic IL
    Dermatol Clin; 2011 Oct; 29(4):677-9. PubMed ID: 21925017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
    Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
    J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of linear IgA disease.
    Ng SY; Venning VV
    Dermatol Clin; 2011 Oct; 29(4):629-30. PubMed ID: 21925008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone cyclophosphamide pulse therapy is highly efficient in autoimmune blistering and connective tissue disorders.
    Manousaridis I; Utikal J; Goerdt S; Booken N
    Eur J Dermatol; 2011; 21(1):129-30. PubMed ID: 21224179
    [No Abstract]   [Full Text] [Related]  

  • 9. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amicrobial pustulosis of the folds affecting a young male without any accompanying autoimmune diseases.
    Okuyama R; Masu T; Kumasaka N; Aiba S; Tagami H
    Dermatology; 2008; 217(2):121-3. PubMed ID: 18477848
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of eosinophilic pustular folliculitis with response to infliximab.
    Hasegawa A; Kobayashi N; Fukumoto T; Asada H
    J Am Acad Dermatol; 2012 Oct; 67(4):e136-7. PubMed ID: 22980264
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral involvement in autoimmune bullous diseases.
    Ramos-e-Silva M; Ferreira A; Jacques Cd
    Clin Dermatol; 2011; 29(4):443-54. PubMed ID: 21679873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the treatment of autoimmune mucocutaneous blistering diseases.
    Ahmed AR
    Int J Periodontics Restorative Dent; 2007 Aug; 27(4):309-10. PubMed ID: 17726986
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmune bullous diseases in Austria.
    Laimer M; Pohla-Gubo G; Kraus L; Nischler E; Bauer JW; Ahlgrimm-Siess V; Hintner H
    Dermatol Clin; 2011 Oct; 29(4):691-8. PubMed ID: 21925021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.
    Liu X; Ma J; Qiu X; Hong D; Wang L; Shi Z
    Eur J Dermatol; 2021 Dec; 31(6):846-847. PubMed ID: 35107075
    [No Abstract]   [Full Text] [Related]  

  • 16. Research in practice: Treatment of autoimmune bullous disorders.
    Hertl M
    J Dtsch Dermatol Ges; 2009 Jun; 7(6):500-5. PubMed ID: 19243480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases.
    Meiss F; Helmbold P; Meykadeh N; Gaber G; Marsch WCh; Fischer M
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):717-9. PubMed ID: 17448012
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of intravenous immunoglobulin in autoimmune bullous diseases.
    Chee SN; Murrell DF
    Dermatol Clin; 2011 Oct; 29(4):565-70. PubMed ID: 21924999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.
    Alaibac M
    Front Immunol; 2018; 9():810. PubMed ID: 29720979
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab for the treatment of autoimmune subepidermal blistering diseases.
    Riquelme-Mc Loughlin C; Estrach T; Morgado-Carrasco D; Fustà-Novell X; Riera-Monroig J; Iranzo P
    Dermatol Ther; 2018 Sep; 31(5):e12687. PubMed ID: 30207027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.